NCT00545779

BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.

'Open, Prospective, Multi-center, Two-part Study of Patient Preference With Monthly Ibandronate Therapy in Women With Postmenopausal Osteoporosis Switched From Once-daily or Once Weekly Alendronate or Risendronate - BONCURE (BONviva for Current Bisphosphonate Users - Regional European Trial)'

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 677 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

This single arm study will assess participant preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis. Participants currently on a daily or weekly regimen of bisphosphonate therapy (alendronate or risedronate) will answer a questionnaire to identify participants who may benefit from a monthly Bonviva regimen. Eligible participants will then discontinue their present bisphosphonate treatment, and switch to monthly Bonviva 150mg per oral (po). At the beginning and end of Bonviva treatment, all participants will complete an Osteoporosis Patient Satisfaction Questionnaire. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

Conditions

• Post-Menopausal Osteoporosis

Interventions

Type	Name	Description
DRUG	Ibandronate	150 mg orally once monthly for 6 months

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2007-10-17
• Last updated: 2016-10-28
• Results posted: 2016-10-28

Locations

32 sites across 6 countries: Albania, Bosnia and Herzegovina, Croatia, North Macedonia, Serbia, Turkey (Türkiye)